X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
subcutaneous omacetaxine mepesuccinate (15) 15
index medicus (14) 14
chronic myelogenous leukemia (13) 13
oncology (12) 12
tyrosine kinase inhibitors (11) 11
chronic myeloid leukemia (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (8) 8
chronic myeloid-leukemia (7) 7
antineoplastic agents - therapeutic use (6) 6
hematology (6) 6
homoharringtonine (6) 6
adult (5) 5
aged (5) 5
antineoplastic agents - pharmacology (5) 5
antineoplastic agents, phytogenic - administration & dosage (5) 5
female (5) 5
follow-up (5) 5
harringtonines - administration & dosage (5) 5
hemic and lymphatic diseases (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - genetics (5) 5
male (5) 5
middle aged (5) 5
pharmacology & pharmacy (5) 5
research (5) 5
tyrosine (5) 5
article (4) 4
chromosome-positive leukemias (4) 4
chronic-phase (4) 4
dasatinib (4) 4
domain mutations (4) 4
imatinib (4) 4
injections, subcutaneous (4) 4
minimal residual disease (4) 4
nilotinib (4) 4
patients receiving imatinib (4) 4
protein kinase inhibitors - therapeutic use (4) 4
review (4) 4
treatment outcome (4) 4
acute lymphoblastic-leukemia (3) 3
animals (3) 3
antineoplastic agents, phytogenic - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
bcr-abl (3) 3
bcr-abl mutations (3) 3
bcr-abl1 (3) 3
cancer (3) 3
cml (3) 3
complete cytogenetic response (3) 3
diagnosed chronic-phase (3) 3
down-regulation (3) 3
harringtonines - adverse effects (3) 3
health aspects (3) 3
imatinib mesylate (3) 3
imatinib resistance (3) 3
infusions, subcutaneous (3) 3
leukemia (3) 3
leukemia, myeloid, chronic-phase - drug therapy (3) 3
mutation (3) 3
neoplasms - drug therapy (3) 3
prognosis (3) 3
protein kinase inhibitors - adverse effects (3) 3
protein kinase inhibitors - pharmacology (3) 3
signal transduction - drug effects (3) 3
stem-cell transplantation (3) 3
abridged index medicus (2) 2
aged, 80 and over (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apoptosis (2) 2
biochemistry & molecular biology (2) 2
cancer research (2) 2
care and treatment (2) 2
chemotherapy (2) 2
chromosomes (2) 2
chronic lymphocytic-leukemia (2) 2
colony-stimulating factor (2) 2
disease progression (2) 2
drug approval (2) 2
drug resistance, neoplasm (2) 2
drug resistance, neoplasm - drug effects (2) 2
drug therapy (2) 2
hematologic neoplasms - drug therapy (2) 2
hematology, oncology and palliative medicine (2) 2
imatinib mesylate therapy (2) 2
interferon-alpha (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - pathology (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - therapy (2) 2
leukemia, myeloid, chronic-phase - mortality (2) 2
lymphomas (2) 2
methods (2) 2
neoplasms - pathology (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
omacetaxine mepesuccinate (2) 2
oncology, experimental (2) 2
open-label (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2013, Volume 71, Issue 1, pp. 35 - 41
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2013, Volume 88, Issue 5, pp. 350 - 354
Omacetaxine mepesuccinate (omacetaxine) is a first‐in‐class cephalotaxine with a unique mode of action, independent of BCR‐ABL, that has shown promising... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | APOPTOSIS | THERAPY | BCR-ABL | IMATINIB | DOWN-REGULATION | HOMOHARRINGTONINE | HEMATOLOGY | FAILURE | NILOTINIB | Drug Resistance, Multiple | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Harringtonines - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Harringtonines - therapeutic use | Protein Synthesis Inhibitors - administration & dosage | Hematopoiesis - drug effects | Maintenance Chemotherapy - adverse effects | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Harringtonines - administration & dosage | Adult | Bone Marrow Cells - drug effects | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - adverse effects | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Bone Marrow Cells - pathology | Induction Chemotherapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Drug Monitoring | Protein Synthesis Inhibitors - adverse effects | Protein Synthesis Inhibitors - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Phenols | Research | Chronic myeloid leukemia | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2013, Volume 13, Issue 5, pp. 584 - 591
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article
XENOBIOTICA, ISSN 0049-8254, 12/2016, Volume 46, Issue 12, pp. 1122 - 1132
1. Omacetaxine mepesuccinate (hereafter referred to as omacetaxine) is a protein translation inhibitor approved by the US Food and Drug Administration for... 
MOLECULAR-BIOLOGY | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | CHRONIC-PHASE | homoharringtonine | DOMAIN MUTATIONS | MASS-BALANCE | metabolites | CHRONIC MYELOID-LEUKEMIA | TYROSINE KINASE INHIBITORS | Disposition | pharmacokinetics | PHARMACOLOGY & PHARMACY | metabolism | TOXICOLOGY | mepesuccinate | metabolite profiling | omacetaxine | IMATINIB RESISTANCE
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 09/2018, Volume 16, Issue 9, pp. 1108 - 1135
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and... 
CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | CHROMOSOME-NEGATIVE METAPHASES | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | ONCOLOGY | STANDARD-DOSE IMATINIB | IN-SITU HYBRIDIZATION | COMPLETE CYTOGENETIC RESPONSE | PATIENTS RECEIVING IMATINIB | IMATINIB MESYLATE THERAPY | MINIMAL RESIDUAL DISEASE
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 01/2016, Volume 14, Issue 14 Suppl 1, pp. S1 - S6
Chronic myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome arising from a reciprocal translocation between chromosomes... 
TYROSINE KINASE INHIBITORS | DOMAIN | INTOLERANT | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | CML | ONCOLOGY | IMATINIB | FOLLOW-UP | DASATINIB | NILOTINIB | CHRONIC MYELOID-LEUKEMIA
Journal Article
Molecular Cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, pp. 56 - 15
Journal Article